van Bladel Diede A G, Stevens Wendy B C, van den Brand Michiel, Kroeze Leonie I, Groenen Patricia J T A, van Krieken J Han J M, Hebeda Konnie M, Scheijen Blanca
Radboud University Medical Center, Department of Pathology, 6525 GA Nijmegen, The Netherlands.
Radboud Institute for Molecular Life Sciences, 6525 GA Nijmegen, The Netherlands.
Cancers (Basel). 2022 Jun 30;14(13):3222. doi: 10.3390/cancers14133222.
Classical Hodgkin lymphoma (cHL) represents a B-cell lymphoproliferative disease characterized by clonal immunoglobulin gene rearrangements and recurrent genomic aberrations in the Hodgkin Reed-Sternberg cells in a reactive inflammatory background. Several methods are available for the molecular analysis of cHL on both tissue and cell-free DNA isolated from blood, which can provide detailed information regarding the clonal composition and genetic alterations that drive lymphoma pathogenesis. Clonality testing involving the detection of immunoglobulin and T cell receptor gene rearrangements, together with mutation analysis, represent valuable tools for cHL diagnostics, especially for patients with an atypical histological or clinical presentation reminiscent of a reactive lesion or another lymphoma subtype. In addition, clonality assessment may establish the clonal relationship of composite or subsequent lymphoma presentations within one patient. During the last few decades, more insight has been obtained on the molecular mechanisms that drive cHL development, including recurrently affected signaling pathways (e.g., NF-κB and JAK/STAT) and immune evasion. We provide an overview of the different approaches to characterize the molecular composition of cHL, and the implementation of these next-generation sequencing-based techniques in research and diagnostic settings.
经典型霍奇金淋巴瘤(cHL)是一种B细胞淋巴增殖性疾病,其特征是在反应性炎症背景下,霍奇金-里德-斯腾伯格细胞中存在克隆性免疫球蛋白基因重排和反复出现的基因组畸变。有几种方法可用于对cHL进行组织和从血液中分离的游离DNA的分子分析,这些方法可以提供有关驱动淋巴瘤发病机制的克隆组成和基因改变的详细信息。涉及检测免疫球蛋白和T细胞受体基因重排的克隆性检测以及突变分析,是cHL诊断的重要工具,特别是对于具有非典型组织学或临床表现、让人联想到反应性病变或其他淋巴瘤亚型的患者。此外,克隆性评估可以确定同一患者体内复合性或后续淋巴瘤表现的克隆关系。在过去几十年中,人们对驱动cHL发展的分子机制有了更多了解,包括反复受影响的信号通路(如NF-κB和JAK/STAT)和免疫逃逸。我们概述了表征cHL分子组成的不同方法,以及这些基于下一代测序的技术在研究和诊断环境中的应用。